Patent attorneys from longtime Mizzou industry partner Novartis will discuss protecting health care innovations and share intellectual property strategies for pharmaceuticals and clinical innovations. Faculty, staff and students from any discipline interested in how medical products are commercialized are encouraged to attend. This event is hosted by the University of Missouri Research Reactor and the Division of Research, Innovation & Impact. 

SPEAKERS

Holger Petersen, Novartis Senior Patent Attorney

Holger has been an in-house intellectual property (IP) counsel at Novartis Pharma in Basel, Switzerland, for over a decade. When Novartis established its Radioligand Therapy business by acquiring Advanced Accelerator Applications and Endocyte, a Purdue University spin-off, Holger became the IP lead for this new technology platform. He manages the nuclear medicine patent portfolio and its related in-licensed IP assets, collaborating with numerous research institutes, including the University of MIssouri Research Reactor.
 

Before joining the Patent Department, Holger gained 10 years of experience in Novartis’ Technical R&D unit as a drug product developer. He studied chemistry at the University of Marburg, Germany, and Imperial College, London, UK, and  completed his doctorate at Marburg’s Institute for Pharmaceutical Technology. He also holds a master's degree with a specialization in International IP law from the University of London (UCL and Queen Mary colleges).

David F. Cauble, Novartis Senior Patent Attorney

David is an IP attorney based in Novartis’ Cambridge office with more than 16 years of experience in patent preparation and procurement. David earned his doctorate in organic chemistry from the University of Texas at Austin, conducted postdoctoral studies at Stanford University in California and earned his law degree at Suffolk University in Massachusetts. He worked as a medicinal chemist at Schering Plough before transitioning to IP law.